🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

58 results for “CERO” Clear

  1. CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion, Alunbrig 30 mg film-coated tablets, Alunbrig 180 mg film-coated tablets, Pemetrexed Viatris 25 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    advanced ALK-positive non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  2. Cyramza 10 mg/ml concentrate for solution for infusion, PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    stomach cancer stage IV with metastases

    phase 2 small molecule active

    1 trial

  3. Dopacis 90 MBq/ml oplossing voor injectie

    CERO THERAPEUTICS HOLDINGS, INC.

    patients with newly discovered brain metastases (non-small cell lung cancer, breast cancer or melanoma) measuring more than 5 mm and explored on MRI

    phase 2 small molecule active

    1 trial

  4. Evaluation of 64Cu-ATSM PET/CT as a predictor of response to neoadjuvant therapy in locally advanced rectal cancer (TEP-64Cu-ATSM-Rectum)

    CERO THERAPEUTICS HOLDINGS, INC.

    Rectal adenocarcinoma

    phase 2 other active

    1 trial

  5. FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, Vectibix 20 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Fluorouracil Accord 50 mg/ml Injektions-/ Infusionslösung, Fluorouracile AHCL 50 mg/ml, Soluzione per iniezione o infusione, SOTORASIB, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, FLUOROURACILE ACCORD 50 mg/ml, solutio

    CERO THERAPEUTICS HOLDINGS, INC.

    colorectal cancer

    phase 2 small molecule active

    1 trial

  6. FRUZAQLA 5 mg hard capsules, FLUOROURACIL, FOLINIC ACID, FLUOROURACIL, IRINOTECAN, OXALIPLATIN, Avastin 25 mg/ml concentrate for solution for infusion., FRUZAQLA 1 mg hard capsules

    CERO THERAPEUTICS HOLDINGS, INC.

    métastatique colorectal cancer

    phase 2 small molecule active

    1 trial

  7. Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Pleural mesothelioma

    phase 2 small molecule active

    1 trial

  8. IMFINZI 50 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer, Poor general status

    phase 2 small molecule active

    1 trial

  9. IMFINZI 50 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    oligometastatic hormone sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  10. IRINOTECAN, FOLINIC ACID, FLUOROURACIL, DOMVANALIMAB, FLUOROURACIL, ZIMBERELIMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    stomach cancer, Esophage, gastro-oesophageal junction adenocarcinoma

    phase 2 small molecule active

    1 trial

  11. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., FLUOROURACIL, CAPECITABINE BIOGARAN 500 mg, comprimé pelliculé, Avastin 25 mg/ml concentrate for solution for infusion., OXALIPLATINE HOSPIRA 5 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IMMUNE INFILTRATE

    phase 2 small molecule active

    1 trial

  12. LEVOFOLINATE DE CALCIUM ZENTIVA 10 mg/ml, solution injectable (IM/IV), Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Bemarituzumab, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, OXALIPLATINE ACCORD 5 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    gastric and gastro-oesophageal junction adenocarcinomas

    phase 2 small molecule active

    1 trial

  13. Lorviqua 100 mg film-coated tablets, Lorviqua 25 mg film-coated tablets

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced ROS1-positive non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  14. MoLuoDan

    China SXT Pharmaceuticals

    Gastric Precancerous Condition

    phase 2 small molecule active

    1 trial

  15. OXALIPLATIN, AFLIBERCEPT, PANITUMUMAB, BEVACIZUMAB, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, IRINOTECAN, FLUOROURACIL, CETUXIMAB, AVELUMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY

    phase 2 small molecule active

    1 trial

  16. PACLITAXEL, LIBTAYO 350 mg concentrate for solution for infusion., CARBOPLATIN

    CERO THERAPEUTICS HOLDINGS, INC.

    Unresectable stage III Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. Puregon 300 IU/0.36 mL solution for injection, Cetrotide 0.25 mg powder and solvent for solution for injection, NOLVADEX 10 mg, comprimé pelliculé, Ovitrelle 250 micrograms solution for injection in pre-filled pen

    CERO THERAPEUTICS HOLDINGS, INC.

    Breast cancer

    phase 2 small molecule active

    1 trial

  18. RElapse in previously irradiated Prostate bed : a phase I/II study of stereotactic Ablative reIRradiation potentiated by Metformine (REPAIR GETUG P16)

    CERO THERAPEUTICS HOLDINGS, INC.

    RElapse in previously irradiated Prostate bed

    phase 2 other active

    1 trial

  19. Tecentriq 1 200 mg concentrate for solution for infusion, OXALIPLATINE HOSPIRA 5 mg/ml, solution à diluer pour perfusion, Avastin 25 mg/ml concentrate for solution for infusion., CAPECITABINE VIATRIS 500 mg, comprimé pelliculé

    CERO THERAPEUTICS HOLDINGS, INC.

    microsatellite stable (MSS) colorectal cancer with liver-dominant metastasis

    phase 2 small molecule active

    1 trial

  20. Xeloda 150 mg film-coated tablets, ELOXATINE 5 mg/ml, solution à diluer pour perfusion, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, ELVORINE 100 mg/10 mL, solution injectable, FLUOROURACILE TEVA 1000 mg/20 ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    colon cancer

    phase 2 small molecule active

    1 trial

  21. Xeloda 150 mg film-coated tablets, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, ELOXATINE 5 mg/ml, solution à diluer pour perfusion, Vectibix 20 mg/ml concentrate for solution for infusion, FLUOROURACILE TEVA 1000 mg/20 ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    metastatic colorectal adenocarcinoma

    phase 2 small molecule active

    1 trial

  22. ivonescimab

    CERO THERAPEUTICS HOLDINGS, INC.

    pleural mesothelioma

    phase 2 small molecule active

    1 trial

  23. volrustomig, Monalizumab

    Pari Pharma GmbH

    cancerology

    phase 2 small molecule active

    1 trial

  24. A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101™) in PatiEnts with Non-Muscle-InVasive BladdER CANCEr Refractory to Standard Treatment (PERSEVERANCE EU)

    CERO THERAPEUTICS HOLDINGS, INC.

    Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources